Osaka spinout Cuorips has added $14.7m to its coffers from investors including vehicles for the institution and Kyoto University, just three months after collecting $19.3m.

Softbank Investment Advisors and existing investor GV contributed to a series C round boosting the drug discovery platform developer's overall funding to over $640m.

The Keio University-backed digital medicine developer has secured $19.3m from a consortium including several Japanese corporations.

Dai-ichi Life, Itochu Technology Ventures, Koshidaka and Toyoshima CVC were among the investors that backed the medical therapy booking platform’s $19.3m round.

Baxter Healthcare was among the investors in the $65m first close of a private placement the biosimilar drug developer has pushed to $100m.

Alphabet subsidiary GV was part of a consortium in a round that will fund the progress of the precision medicine developer's lead drug candidate into the clinic.

The biopharmaceutical company has provided $40m in seed capital for the newly launched immuno-oncology drug developer.

Osaka spinout Cuorips has added $14.7m to its coffers from investors including CellSource and Fujifilm, just three months after collecting $19.3m.

RA Capital Management and Rock Springs Capital have co-led a series B round for the gene editing technology developer spun out of Stanford six months ago.

Feature: artificial intelligence driving disease prevention, digital health enables personalised medicine, investment takes off